OA07.07 PARP1 Inhibitors Enhanced IFNγ-Induced PD-L1 Expression in LKB1-Mutant Lung Cancer

STK11/LKB1 mutations define a molecular subtype of lung adenocarcinoma with a distinct T cell-excluded tumor immune microenvironment and no programmed death-ligand 1 (PD-L1) expression on tumor cells, classified as type II cancers (PD-L1−/TIL−). Dissecting the underlying mechanism of tumor PD-L1 regulation might become one of the breakthroughs to reverse this “cold” state.